DK3609898T3 - Forbindelser, der er nyttige som ret-hæmmere - Google Patents

Forbindelser, der er nyttige som ret-hæmmere Download PDF

Info

Publication number
DK3609898T3
DK3609898T3 DK18719276.0T DK18719276T DK3609898T3 DK 3609898 T3 DK3609898 T3 DK 3609898T3 DK 18719276 T DK18719276 T DK 18719276T DK 3609898 T3 DK3609898 T3 DK 3609898T3
Authority
DK
Denmark
Prior art keywords
compounds useful
ret inhibitors
ret
inhibitors
compounds
Prior art date
Application number
DK18719276.0T
Other languages
English (en)
Inventor
Allan Jordan
Rebecca Newton
George Hynd
Jonathan Mark Sutton
Bohdan Waszkowycz
Original Assignee
Cancer Research Tech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cancer Research Tech Ltd filed Critical Cancer Research Tech Ltd
Application granted granted Critical
Publication of DK3609898T3 publication Critical patent/DK3609898T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Steroid Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
DK18719276.0T 2017-04-13 2018-04-13 Forbindelser, der er nyttige som ret-hæmmere DK3609898T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1705971.8A GB201705971D0 (en) 2017-04-13 2017-04-13 Inhibitor compounds
PCT/GB2018/050986 WO2018189553A1 (en) 2017-04-13 2018-04-13 Compounds useful as ret inhibitors

Publications (1)

Publication Number Publication Date
DK3609898T3 true DK3609898T3 (da) 2022-09-05

Family

ID=58744532

Family Applications (1)

Application Number Title Priority Date Filing Date
DK18719276.0T DK3609898T3 (da) 2017-04-13 2018-04-13 Forbindelser, der er nyttige som ret-hæmmere

Country Status (19)

Country Link
US (3) US11352361B2 (da)
EP (2) EP4105219A1 (da)
JP (2) JP7277376B2 (da)
CN (2) CN110506043B (da)
AU (3) AU2018252251B2 (da)
BR (1) BR112019021231A2 (da)
CA (1) CA3059134A1 (da)
DK (1) DK3609898T3 (da)
ES (1) ES2925077T3 (da)
GB (1) GB201705971D0 (da)
HR (1) HRP20221040T1 (da)
HU (1) HUE059716T2 (da)
LT (1) LT3609898T (da)
PL (1) PL3609898T3 (da)
PT (1) PT3609898T (da)
RS (1) RS63514B1 (da)
RU (1) RU2760669C2 (da)
SI (1) SI3609898T1 (da)
WO (1) WO2018189553A1 (da)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4331585A3 (en) 2015-11-02 2024-05-15 Blueprint Medicines Corporation Inhibitors of ret
GB201705971D0 (en) * 2017-04-13 2017-05-31 Cancer Res Tech Ltd Inhibitor compounds
WO2019143991A1 (en) * 2018-01-18 2019-07-25 Array Biopharma Inc. SUBSTITUTED PYRAZOLO[3,4-d]PYRIMIDINE COMPOUNDS AS RET KINASE INHIBITORS
CA3087972C (en) 2018-01-18 2023-01-10 Array Biopharma Inc. Substituted pyrazolyl[4,3-c]pyridinecompounds as ret kinase inhibitors
TWI802635B (zh) 2018-01-18 2023-05-21 美商亞雷生物製藥股份有限公司 作為ｒｅｔ激酶抑制劑之經取代吡咯并[2,3-d]嘧啶化合物
LT3773589T (lt) 2018-04-03 2024-02-12 Blueprint Medicines Corporation Ret inhibitorius, skirtas naudoti vėžiui gydyti, esant ret pakitimui
WO2020033838A2 (en) 2018-08-10 2020-02-13 Blueprint Medicines Corporation Treatment of egfr-mutant cancer
WO2020094084A1 (zh) * 2018-11-07 2020-05-14 南京明德新药研发有限公司 作为ret抑制剂的三并环衍生物
CN111454268B (zh) * 2019-01-18 2023-09-08 明慧医药（上海）有限公司 作为布鲁顿酪氨酸激酶抑制剂的环状分子
EP3950685A4 (en) * 2019-04-03 2022-12-14 Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd. Baiyunshan Pharmaceutical General Factory PYRAZOLOPYRIDINE COMPOUND USED AS RET INHIBITOR AND USES THEREOF
CN113214294A (zh) * 2020-06-10 2021-08-06 深圳铂立健医药有限公司 三环化合物、药物组合物及其应用
US20230365596A1 (en) * 2020-09-29 2023-11-16 Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd. Baiyunshan Pharmaceutical General Factory Crystal forms of pyridopyrazole compounds and preparation method therefor
EP4370207A1 (en) * 2021-07-12 2024-05-22 Nido Biosciences, Inc. Bicyclic compounds as androgen receptor modulators
WO2023064843A1 (en) * 2021-10-15 2023-04-20 Stemline Therapeutics, Inc. Inhibitors of mutant ret kinases for use in treating cancer

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0322779A3 (en) 1987-12-29 1991-05-08 Yoshitomi Pharmaceutical Industries, Ltd. Benzolactam compounds and pharmaceutical uses thereof
US5480883A (en) 1991-05-10 1996-01-02 Rhone-Poulenc Rorer Pharmaceuticals Inc. Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
KR19990082463A (ko) 1996-02-13 1999-11-25 돈 리사 로얄 혈관 내피 성장 인자 억제제로서의 퀴나졸린유도체
CN1116286C (zh) 1996-03-05 2003-07-30 曾尼卡有限公司 4－苯胺基喹唑啉衍生物
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
KR100838617B1 (ko) 1999-02-10 2008-06-16 아스트라제네카 아베 혈관형성 억제제로서의 퀴나졸린 유도체
IL152682A0 (en) 2000-05-31 2003-06-24 Astrazeneca Ab Indole derivatives with vascular damaging activity
UA73993C2 (uk) 2000-06-06 2005-10-17 Астразенека Аб Хіназолінові похідні для лікування пухлин та фармацевтична композиція
CN1255391C (zh) 2000-07-07 2006-05-10 安吉奥金尼药品有限公司 作为血管破坏剂的colchinol衍生物
PL359181A1 (en) 2000-07-07 2004-08-23 Angiogene Pharmaceuticals Limited Colchinol derivatives as angiogenesis inhibitors
US7119200B2 (en) 2002-09-04 2006-10-10 Schering Corporation Pyrazolopyrimidines as cyclin dependent kinase inhibitors
US7429596B2 (en) 2003-06-20 2008-09-30 The Regents Of The University Of California 1H-pyrrolo [2,3-D] pyrimidine derivatives and methods of use thereof
US9512125B2 (en) 2004-11-19 2016-12-06 The Regents Of The University Of California Substituted pyrazolo[3.4-D] pyrimidines as anti-inflammatory agents
WO2006092430A1 (de) 2005-03-03 2006-09-08 Universität des Saarlandes Selektive hemmstoffe humaner corticoidsynthasen
EP1951724B1 (en) 2005-11-17 2011-04-27 OSI Pharmaceuticals, Inc. FUSED BICYCLIC mTOR INHIBITORS
AR057960A1 (es) 2005-12-02 2007-12-26 Osi Pharm Inc Inhibidores de proteina quinasa biciclicos
US20080299113A1 (en) * 2005-12-19 2008-12-04 Arnold Lee D Combined treatment with and composition of 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitor and anti-cancer agents
CA2635231C (en) * 2005-12-29 2014-07-15 Abbott Laboratories Protein kinase inhibitors
GB0610242D0 (en) 2006-05-23 2006-07-05 Novartis Ag Organic compounds
JP2008063278A (ja) 2006-09-07 2008-03-21 Fujifilm Finechemicals Co Ltd １−ピリジン−４−イル−インドール類の製造方法
EP2201840B1 (en) 2006-09-22 2011-11-02 Pharmacyclics, Inc. Inhibitors of Bruton's Tyrosine Kinase
JP2010532756A (ja) 2007-07-06 2010-10-14 オーエスアイ・ファーマスーティカルズ・インコーポレーテッド ｍＴＯＲＣ１及びｍＴＯＲＣ２の両方の阻害剤を含む組み合わせ抗癌療法
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
RU2537549C2 (ru) * 2008-01-04 2015-01-10 Интелликайн ЭлЭлСи Некоторые химические структуры, композиции и способы
US8703777B2 (en) 2008-01-04 2014-04-22 Intellikine Llc Certain chemical entities, compositions and methods
US20110224223A1 (en) 2008-07-08 2011-09-15 The Regents Of The University Of California, A California Corporation MTOR Modulators and Uses Thereof
AU2009268611B2 (en) 2008-07-08 2015-04-09 Intellikine, Llc Kinase inhibitors and methods of use
JP5731978B2 (ja) * 2008-09-26 2015-06-10 インテリカイン， エルエルシー 複素環キナーゼ阻害剤
US8476282B2 (en) * 2008-11-03 2013-07-02 Intellikine Llc Benzoxazole kinase inhibitors and methods of use
WO2010059593A1 (en) 2008-11-18 2010-05-27 Intellikine, Inc. Methods and compositions for treatment of ophthalmic conditions
KR101061599B1 (ko) 2008-12-05 2011-09-02 한국과학기술연구원 비정상 세포 성장 질환의 치료를 위한 단백질 키나아제 저해제인 신규 인다졸 유도체, 이의 약학적으로 허용가능한염 및 이를 유효성분으로 함유하는 약학적 조성물
CA3022722A1 (en) 2009-11-05 2011-05-12 Rhizen Pharmaceuticals S.A. Pi3k protein kinase modulators
US9765037B2 (en) 2010-01-28 2017-09-19 University Of Washington Through Its Center For Commercialization Compositions and methods for treating toxoplasmosis, cryptosporidiosis, and other apicomplexan protozoan related diseases
WO2011094628A1 (en) 2010-01-28 2011-08-04 University Of Washington Compositions and methods for treating toxoplasmosis. cryptosporidiosis and other apicomplexan protozoan related diseases
WO2011153553A2 (en) 2010-06-04 2011-12-08 The Regents Of The University Of California Methods and compositions for kinase inhibition
US20110304649A1 (en) * 2010-06-10 2011-12-15 Microsoft Corporation Character selection
WO2012006619A2 (en) 2010-07-09 2012-01-12 Northeastern University ANTIPARASITIC AGENTS BASED ON mTOR INHIBITORS
US9295673B2 (en) 2011-02-23 2016-03-29 Intellikine Llc Combination of mTOR inhibitors and P13-kinase inhibitors, and uses thereof
WO2012151562A1 (en) 2011-05-04 2012-11-08 Intellikine, Llc Combination pharmaceutical compositions and uses thereof
EP2741747A1 (en) 2011-08-10 2014-06-18 Novartis Pharma AG JAK P13K/mTOR COMBINATION THERAPY
JP6342805B2 (ja) 2011-09-02 2018-06-13 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 置換ピラゾロ［３，４−ｄ］ピリミジンおよびその用途
US20140377285A1 (en) 2011-11-08 2014-12-25 Intellikine, Llc Treatment regimens using multiple pharmaceutical agents
CA2856803A1 (en) 2011-11-23 2013-05-30 Intellikine, Llc Enhanced treatment regimens using mtor inhibitors
US8501724B1 (en) 2012-01-31 2013-08-06 Pharmacyclics, Inc. Purinone compounds as kinase inhibitors
US8889730B2 (en) 2012-04-10 2014-11-18 Pfizer Inc. Indole and indazole compounds that activate AMPK
US9738610B2 (en) 2012-09-24 2017-08-22 Whitehead Institute For Biomedical Research Indazole derivatives and uses thereof
GB201217285D0 (en) 2012-09-27 2012-11-14 Univ Central Lancashire Indole derivatives
WO2014151147A1 (en) 2013-03-15 2014-09-25 Intellikine, Llc Combination of kinase inhibitors and uses thereof
CA2907726A1 (en) 2013-03-22 2014-09-25 Millennium Pharmaceuticals, Inc. Combination of catalytic mtorc1/2 inhibitors and selective inhibitors of aurora a kinase
US9682083B2 (en) * 2013-05-14 2017-06-20 Nerviano Medical Sciences S.R.L. Pyrrolo[2,3-D]pyrimidine derivatives, process for their preparation and their use as kinase inhibitors
US20210317140A1 (en) 2013-10-18 2021-10-14 Medivation Technologies, Inc. Heterocyclic Compounds and Methods of Use
US20160272645A1 (en) 2013-10-18 2016-09-22 Medivation Technologies, Inc. Heterocyclic Compounds and Methods of Use
GB201321146D0 (en) 2013-11-29 2014-01-15 Cancer Rec Tech Ltd Quinazoline compounds
US10221181B2 (en) 2014-11-14 2019-03-05 Nerviano Medical Sciences S.R.L. 6-amino-7-bicyclo-7-deaza-purine derivatives as protein kinase inhibitors
US10350211B2 (en) 2015-01-26 2019-07-16 University Of Washington Bumped kinase inhibitor compositions and methods for treating cancer
KR101766194B1 (ko) * 2015-08-07 2017-08-10 한국과학기술연구원 RET 키나아제 저해제인 신규 3-(이속사졸-3-일)-피라졸로[3,4-d]피리미딘-4-아민 화합물
EP3334430A4 (en) 2015-08-13 2019-02-06 San Diego State University Foundation ATROPISOMERISM FOR INCREASED KINASE HEMMER ELECTIVITY
TW201722958A (zh) * 2015-09-15 2017-07-01 葛蘭素史克智慧財產（第二）有限公司 化學化合物
WO2017160717A2 (en) 2016-03-15 2017-09-21 Memorial Sloan Kettering Cancer Center Method of treating diseases using kinase modulators
US10844067B2 (en) 2016-04-15 2020-11-24 Cancer Research Technology Limited Heterocyclic compounds as RET kinase inhibitors
KR102706837B1 (ko) 2016-04-15 2024-09-19 캔써 리서치 테크놀로지 리미티드 Ret 키나아제 억제제로서의 헤테로사이클릭 화합물
GB201705971D0 (en) * 2017-04-13 2017-05-31 Cancer Res Tech Ltd Inhibitor compounds

Also Published As

Publication number Publication date
GB201705971D0 (en) 2017-05-31
HRP20221040T1 (hr) 2022-11-11
EP3609898A1 (en) 2020-02-19
US20200157107A1 (en) 2020-05-21
LT3609898T (lt) 2022-09-12
EP3609898B1 (en) 2022-06-01
ES2925077T3 (es) 2022-10-13
RU2019132155A3 (da) 2021-05-13
HUE059716T2 (hu) 2022-12-28
RS63514B1 (sr) 2022-09-30
JP2023103326A (ja) 2023-07-26
CN110506043B (zh) 2022-11-01
RU2760669C2 (ru) 2021-11-29
SI3609898T1 (sl) 2022-11-30
US20220348585A1 (en) 2022-11-03
AU2024213175A1 (en) 2024-09-12
EP4105219A1 (en) 2022-12-21
AU2022202325A1 (en) 2022-04-28
US11352361B2 (en) 2022-06-07
JP2020516636A (ja) 2020-06-11
CN115785100A (zh) 2023-03-14
US11680068B2 (en) 2023-06-20
CA3059134A1 (en) 2018-10-18
RU2019132155A (ru) 2021-05-13
JP7536949B2 (ja) 2024-08-20
BR112019021231A2 (pt) 2020-04-28
AU2018252251B2 (en) 2022-03-31
PT3609898T (pt) 2022-08-25
US20240132504A1 (en) 2024-04-25
AU2018252251A1 (en) 2019-10-17
PL3609898T3 (pl) 2022-09-26
AU2022202325B2 (en) 2024-05-23
JP7277376B2 (ja) 2023-05-18
CN110506043A (zh) 2019-11-26
WO2018189553A1 (en) 2018-10-18

Similar Documents

Publication Publication Date Title
DK3609898T3 (da) Forbindelser, der er nyttige som ret-hæmmere
FR24C1016I1 (fr) Inhibiteurs de ret
DK3873903T3 (da) Substituerede 6-azabenzimidazolforbindelser som hpk1-hæmmere
DK3582780T3 (da) Aminopyrimidinforbindelser, der er anvendelige som SSAO-inhibitorer
DK3442980T3 (da) Heterocykliske forbindelser som ret-kinase-hæmmere
DK3697785T3 (da) Imidazo-pyridine forbindelser som pad-inhibitorer
DK3684767T3 (da) Heterocykliske forbindelser som pad-inhibitorer
DK3656769T3 (da) Aryl-phosphor-oxygen-forbindelse som egfr-kinase-inhibitor
DK3371190T3 (da) Heterocykliske forbindelser som pi3k-gamma-inhibitorer
DK3461821T3 (da) Indolcarboxamidforbindelser, der er brugbar som kinasehæmmere
DK3472167T3 (da) Heterocykliske forbindelser som immunomodulatorer
DK3377488T3 (da) Heterocykliske forbindelser som immunomodulatorer
DK3704120T3 (da) Heterocykliske forbindelser som prmt5-inhibitorer
DK3768674T3 (da) Aminopyrimidinderivater som ctps1-hæmmere
DK3728252T3 (da) 4-azaindolforbindelser
DK3390395T3 (da) Forbindelser, der kan anvendes som kinase-inhibitorer
DK3277677T3 (da) 1-cyano-pyrrolidinforbindelser som usp30-hæmmere
DK3230278T3 (da) Hidtil ukendte methyl-piperidin-forbindelser, som er anvendelige til inhibering af mikrosomale prostaglandin-e2-syntase-1
DK3442535T3 (da) Heterocykliske stoffer som as ret-kinase-hæmmere
DK3313832T3 (da) 3-tetrazolyl-benzen-1,2-disulfonamidderivater som metallo-beta- lactamase-hæmmere
DK3235819T3 (da) Pyrrolopyrimidinforbindelser, der er anvendelige som JAK-inhibitorer
DK3294713T3 (da) Substituerede tetrahydroquinolinonforbindelser som ror-gamma-modulatorer
DK3003038T3 (da) 2h-1,2,3-triazolderivater som inhibitorer af fibrose
DK3762368T3 (da) Aminopyrazindiolforbindelser som pi3k-y-inhibitorer
DK3552017T3 (da) Forbindelser, der er anvendelige som ripk1-inhibitorer